Onward wins FDA nod for non-invasive spinal cord stim
December 19, 2024
Onward Medical announced today that it received FDA de novo clearance for its ARC-EX spinal cord stimulation (SCS) system.
Onward Medical announced today that it received FDA de novo clearance for its ARC-EX spinal cord stimulation (SCS) system.
Roivios Initiates Landmark Study to Demonstrate Safety and Efficacy of an Innovative Renal Assist Device for Cardiac Surgery Patients With Kidney Disease
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant.
BiVacor announced today that it completed the first phase of an FDA early feasibility study (EFS) for its Total Artificial Heart (TAH).
Researchers from UC Irvine’s Departments of Radiological Sciences and Biomedical Engineering recently published a study in the journal Science Advances in which they introduce a technology that achieves 3D imaging with a single X-ray projection called X-ray–Induced Acoustic Computed Tomography (XACT).
Smith+Nephew (NYSE: SNN)+
announced that it received FDA clearance for its stemless anatomic total shoulder for the Aetos system.
CardioFocus announced today that investigators completed the first series of treatments in a study of its OptiShot pulsed-field ablation system.
Infertility affects an estimated 186 million people worldwide, with fallopian tube obstruction contributing to 11–67% of female infertility cases. In AIP Advances researchers at the SIAT Magnetic Soft Microrobots Lab have developed an innovative solution using a magnetically driven robotic microscrew to treat fallopian tube blockages.
Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.
ABBOTT PARK, Ill., Dec. 17, 2024 /PRNewswire/ — Abbott (NYSE: ABT) today announced the successful completion of the world’s first in-human leadless left bundle branch area pacing (LBBAP) procedures using the company’s investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system, as part of a feasibility study.